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Introduction
We previously described a new autosomal recessively
inherited autoinflammatory syndrome in two Turkish
patients, who were second-degree cousins. Their clinical
features included recurrent inflammatory attacks lasting
3-10 days since the first year of life, which are character-
ized by fever, erythematous or urticarial rash with hyper-
esthesia, serositis and edema on the face and extremities.
Both patients eventually developed a lymphedema symme-
trically affecting lower extremities and genitalia. Using a
homozygosity mapping approach and targeted capture
array based sequencing, we identified a homozygous inser-
tion mutation in the exon 3 of the MyoD family inhibitor
domain containing gene (MDFIC), causing a frameshift
and inhibiting the translation of its functional cysteine-
rich C-terminal domain. We herein report another patient
of Italian origin and also their response to anakinra
treatment.
Case report
Italian patient, a 11 year-old girl healthy unrelated parents,
had a history of caesarean section at 33th week of preg-
nancy, because of fetal subcutaneous tissue edema and
pleural effusion. Within the first 24 h, she developed
respiratory distress, and pleural effusion was drained the
intensive care unit. She required ventilatory support, anti-
biotics and diuretics for 2 months. At the age of 9 months
hearing loss due to mutation 35delG of GJB2 gene was
detected and cochlear implantation was subsequently
done. At the age of 2 yr, she started to have attacks of
fever, limb edema, severe pleural and pericardial effusions
requiring urgent pleural and pericardial fluid drainage.
Laboratory investigations showed a severe anemia and ele-
vated acute phase response, and she only responded to
high dose methylprednisolone. At the age of 8 yr, she had
recurrent attacks during tapering of steroids. Anakinra
was started at the dosage of 2 mg/kg/day with a dramatic
control of inflammatory manifestations and acute phase
response. After 6 months of continuous treatment ana-
kinra was tapered to every other day injections. Sequen-
cing of the MDFIC gene of this patient revealed the same
insertion mutation causing a frameshift.
Similarly, two Turkish cousins first tried canakinumab
150 mg every 4 weeks, but they continued to experience
attacks on this treatment up to 3 to 4 months. Their treat-
ment switched to anakinra during the last 4 months, and a
favorable response (complete in the elder, and partial in
the younger) was observed in both clinical and laboratory
findings.
Discussion
Identification of the same MDFIC gene mutation in an
Italian patient with similar manifestations confirms the
association of this variation with AISLE. Differential
response to anakinra in those patients may suggest the
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